Physician profile
Beth M Mitchell
NPI 1598702524
$5,634.32
in general payments reported to CMS, 2019-2025
24 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $697 · 2022: $1,129 · 2023: $1,442 · 2024: $1,327 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.95 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.18 | 2021-2025 | |
| Incyte Corporation | $663.00 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $612.83 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $450.02 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $351.42 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Janssen Biotech, INC. | $346.02 | 2021-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $242.91 | 2021-2025 | |
| Leo Pharma INC. | $240.39 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $239.07 | 2021-2025 | |
| Dermavant Sciences, INC. | $234.89 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $212.61 | 2022-2025 | Sotyktu |
| Amgen INC. | $181.30 | 2021-2024 | Otezla |
| Lilly USA, LLC | $122.26 | 2021-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $79.49 | 2023-2025 | Nemluvio, Epsolay |
| Vyne Pharmaceuticals INC. | $61.05 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $51.18 | 2024-2025 | Zoryve |
| Allergan, INC. | $37.42 | 2021-2022 | |
| Merz North America, INC. | $31.30 | 2022 | |
| Organogenesis INC. | $30.56 | 2025 | Puraply Wound Matrix |
| Almirall LLC | $30.45 | 2022-2024 | Klisyri |
| Organon LLC | $26.58 | 2025 | |
| Ucb, INC. | $22.54 | 2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.14 | 2021 | |
| Lnhc, INC | $14.71 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.